USA flag logo/image

An Official Website of the United States Government

EGF/Gastrin for islet cell regeneration

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93730
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
DK084724
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PHARMAIN CORPORATION
19805 N. Creek Pkwy, Suite 200 Bothell, WA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: EGF/Gastrin for islet cell regeneration
Agency: HHS
Contract: 1R43DK084724-01
Award Amount: $443,608.00
 

Abstract:

DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard of treatment, injected insulin. Transplantation of panc reatic islet cells in combination with immunosuppressant to avoid immune rejection is restricted to a subgroup of diabetics and is limited by the shortage in availability of donor islets. A recent reports demonstrate that a combination therapy of Epidermal Growth Factor (EGF) and gastrin increases beta cell mass and reverses hyperglycemia in diabetic mice and rats. Importantly, the islet neogenesis that resulted from the above experiment appears to result in cells that are resistant to autoimmunity, offerin g exciting prospects for the reversal of Type 1 diabetes. Because of short half-life (minutes) of both gastrin and EGF, these studies used analogues of EGF and gastrin which were administered twice daily by IP injection (mice) or by infusion (rats). The ov erall goal of this proposal is to formulate injectable native EGF and gastrin in a stable form with half-life of at least 24 hrs and would require only one injection every 2 days instead of frequent injections or infusion. Our company, PharmaIn, owns a pro prietary set of technologies for the reversible binding of peptides and/or proteins to injectable drug nanocarriers. These nanocarriers protect drug from degradation and maintain fixed low concentration of free drugs minimizing side effects and toxicities. In addition, these nanocarriers tend to accumulate at sites of high vascular permeability or inflammations. Since Type 1 diabetic patients are believed to have a mild chronic pancreatic inflammation, the nanocarriers will localize in the pancreas, potenti ally minimizing side effects of growth factors in other areas. One of our goals is to develop this delivery system for native EGF and gastrin to cure diabetes. Additionally, we propose, in parallel, a second approach to improving EGF and gastrin combinatio n therapy. We propose to indirectly induce gastrin secretion by the administration of an orally available proton pump inhibitor (omeprazole) shown previously to increase gastrin levels up to 10 fold. This approach, if successful, has the distinct advantage of replacing labile gastrin with an FDA-approved orally available OTC medication allowing for easy delivery, cost effective treatment and rapid FDA approval. We will quickly test EGF infusion and oral proton pump inhibitor for their ability to induce isle t cell neogenesis (Aim1) and in parallel separately formulate EGF and gastrin (Aim 2). In aim 3, we will determine in vivo pharmacokinetics of formulated EGF, and gastrin if needed. Phase II studies will involve comprehensive validation and evaluation of t he combination treatment with either nanocarrier formulated EGF and gastrin or nanocarrier formulated EGF and oral proton pump inhibitor to larger groups of animals and to do safety study in two animal species (small and large) as required to prepare for I ND. PUBLIC HEALTH RELEVANCE: This Phase I application is aimed toward developing an injectable nanocarrier-stabilized native EGF that can be used to treat and cure diabetes in combination with either nanocarrier- stabilized native gastrin or oral proton pu mp inhibitor available over the counter. This will be a cost saving treatment to cure or alleviate suffering of people with diabetes and reduce its economic burden to society. The eventual goal is FDA filing of an IND application.

Principal Investigator:

Gerardo M. Castillo
2065681499
GCASTILLO@PHARMAIN.COM

Business Contact:

Gerardo M. Castillo
ebolotin@pharmain.com
Small Business Information at Submission:

PHARMAIN CORPORATION
720 BROADWAY, STE 511 SEATTLE, WA 98122

EIN/Tax ID: 364357862
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No